<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198588</url>
  </required_header>
  <id_info>
    <org_study_id>ARG-HIT-CVD</org_study_id>
    <nct_id>NCT00198588</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia</brief_title>
  <official_title>Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Labour and Welfare, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate efficacy and safety of argatroban in the patients
      with heparin-induced thrombocytopenia (HIT)/ HIT and thrombosis syndrome (HITTS). This
      multi-center trial covers mainly the patients with cardiovascular diseases. Subjects are
      included in the trial when they are clinically diagnosed of HIT/HITTS. Initial dose of
      argatroban is 0.7μg/kg/min, which is about one-third of the approved dose in the US. The
      reason of the lower initial dose is that the approved dose of argatroban in Japan (for the
      treatment of ischemic stroke) is about 0.7μg/kg/min and safety of higher doses of the drug
      are not confirmed. A sub-study of pharmacokinetics is simultaneously conducted to reveal the
      relationship among the dose, aPTT, and blood drug concentration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death, new thrombosis, amputation</measure>
    <time_frame>till 37 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of anticoagulation therapy</measure>
    <time_frame>till 37 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of thrombocytopenia</measure>
    <time_frame>till 37 days</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Heparin-Induced Thrombocytopenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>argatroban</intervention_name>
    <description>beginning dose: 0.7microgram/kg/H</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males of non-pregnant females &gt;=20 and &lt;=80 years of age

          2. Those with the diagnosis of HIT or HITTS made by the following diagnostic criteria, or
             those who have positive results of HIT antibody

               -  diagnostic criteria of HIT

               -  a fall in platelet count to less than 100,000/μL or a 50% decrease in platelets
                  after the initiation of heparin therapy with no apparent explanation other than
                  HIT

               -  diagnostic criteria of HITTS

                    -  those who met the diagnosis criteria of HIT

                    -  presence of an arterial or venous thrombosis documented by appropriate
                       imaging technique (ultrasound, angiography etc.) or supported by clinical
                       evidence such as a myocardial infarction, stroke, pulmonary embolism, or
                       other clinical indications of vascular occlusion(absence of pulse, cold,
                       cyanotic extremities, etc.)

               -  patients with history of HIT/HITTS with positive test results (HIT antibody or
                  platelet function test) could be enrolled without present thrombocytopenia

          3. patients willing and able to give informed consent

        Exclusion Criteria:

          1. any condition which in the investigator's opinion, contraindicated the use of
             argatroban or endangered the patient if he or she participated in this trial

          2. clinically significant or uncontrolled endocrine, renal, pulmonary, gastrointestinal,
             or psychiatric disorder of sufficient severity that the investigator deemed
             antithrombotic therapy with argatroban to be contraindicated

          3. unexplained aPTT&gt;200% of control at baseline

          4. documented coagulation disorder or unexplained bleeding diathesis unrelated to HIT

          5. lumbar puncture within the past 7 days

          6. known clinical site of bleeding. Patients with a known site of clinical bleeding could
             be enrolled if the investigator deemed the risk of continued thrombosis outweighed the
             potential bleeding risk

          7. serious liver disfunction

          8. females of known or suspected pregnancy

          9. breast feeding females

         10. participation in other clinical drug trials within the past 30 days

         11. history of hypersensitivity to argatroban

         12. concomitant use of cimetidine

         13. previous participation in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hitonobu TOMOIKE, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>4600001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>4668560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>4668650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hakodate National Hospital</name>
      <address>
        <city>Hakodate</city>
        <state>Hokkaido</state>
        <zip>0418512</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>0030804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Hukuoka</state>
        <zip>8300011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>6500017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City General Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>6500046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>0208505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>2591193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>5148507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>5658565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakakibara Memorial Hospital</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <zip>1830003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Iwakuni Clinical Center</name>
      <address>
        <city>Iwakuni</city>
        <state>Yamaguchi</state>
        <zip>7408510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>7558505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Second Red Cross Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>6028026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>6068507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>1138655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Tokyo Medical Center</name>
      <address>
        <city>Tokyo</city>
        <zip>1528902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>November 11, 2008</last_update_submitted>
  <last_update_submitted_qc>November 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Haruko Yamamoto</name_title>
    <organization>National Cardiovascular Center</organization>
  </responsible_party>
  <keyword>heparin-induced thrombocytopenia</keyword>
  <keyword>argatroban</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>thrombosis</keyword>
  <keyword>amputation</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Argatroban</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

